GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:27 2026-02-11 am EST			5-day change	1st Jan Change
2,150.00 ^GBX	-0.83%		+10.51%	+17.84%

07:16am	Bernstein Upbeat on GSK Amid Upcoming Catalysts; Price Target, Forecasts Revised	MT
06:07pm	FDA refuses to review Moderna's influenza vaccine application	RE

GSK : Berenberg reaffirms its Neutral rating

Published on 01/08/2026 at 09:56 am EST

MarketScreener with dpa-AFX Analyser

GSK PLC

-0.83%

In a research note published by Luisa Hector, Berenberg gives a Neutral rating to the stock. The target price remains unchanged at GBX 1660.

Latest news about GSK plc

07:16am	Bernstein Upbeat on GSK Amid Upcoming Catalysts; Price Target, Forecasts Revised	MT
06:07pm	FDA refuses to review Moderna's influenza vaccine application	RE
Feb. 10	European Stocks Mostly Lower in Tuesday Trading; UK Regulator Seeks Views on Apple, Google Competition Commitments	MT
Feb. 10	Quest Diagnostics Incorporated announces an Increase in Equity Buyback	CI
Feb. 10	Tranche Update on Quest Diagnostics Incorporated's Equity Buyback Plan announced on October 20, 2010.	CI
Feb. 10	GSK's RSV Vaccine Arexvy Accepted for Regulatory Review in China for Older Adults	MT
Feb. 10	GSK RSV vaccine Arexvy accepted for review in China for adults over 60	AN
Feb. 10	GSK says regulatory decision on Arexvy expected in 2027	RE
Feb. 10	Chinese Regulator Accepts GSK's Arexvy Vaccine for Review	MT
Feb. 10	GSK plc's RSV Vaccine Accepts for Review by China's Center for Drug Evaluation for the Prevention of Lower Respiratory Syncytial Virus Disease	CI
Feb. 09	Deutsche cuts Unilever; Jefferies cuts Greggs	AN
Feb. 06	European Stocks Track Higher in Friday Trading; Stellantis Tanks on $26.5 Billion Write-Down	MT
Feb. 06	GSK Chair Jonathan Symonds buys GBP53,000 in shares	AN
Feb. 06	GSK plc Announces Nucala (Mepolizumab) Approval by European Commission for Treatment of Chronic Obstructive Pulmonary Disease	CI
Feb. 06	Markets Ask the Obvious Question
Feb. 06	GSK Says European Commission Approves Nucala to Treat Chronic Obstructive Pulmonary Disease	MT
Feb. 06	Oddo BHF cuts Wizz Air and Ryanair	AN
Feb. 06	FTSE 100 falls as AI fears pressure data stocks	AN
Feb. 06	EU regulator greenlights GSK lung disease therapy Nucala	AN
Feb. 06	UK house prices rise more than expected in January	AN
Feb. 06	GSK Wins EU Nod for Nucala in Uncontrolled Chronic Obstructive PulmonaryDisease	MT
Feb. 06	GSK : Receives a Sell rating from JP Morgan	ZD
Feb. 06	GSK says Nucala COPD approved by the European Commission	RE
Feb. 06	Markets are seasick
Feb. 06	AlphaValue/Baader Europe Keeps 'Favorable Stance' on GSK After Q4 2025 Beat	MT

GSK plc is a global biopharma company. The Companyâ€™s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

68,629

Sector

Pharmaceuticals

Calendar

Apr. 29 - Q1 2026 Earnings Release

More about the company